The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,060,784 in first-year total cost, median $776,926.
Most frequent study sections
- Neurological Sciences and Disorders A Study Section[NSD-A]3
- Neurological Sciences and Disorders B Study Section[NSD-B]2
Most frequent institutions
- BETH ISRAEL DEACONESS MEDICAL CENTER1
- JOHNS HOPKINS UNIVERSITY1
- UNIVERSITY OF COLORADO DENVER1
- UNIVERSITY OF MICHIGAN AT ANN ARBOR1
- UNIVERSITY OF UTAH1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury1U01NS103882-01 | KANNAN, SUJATHARANGARAMANUJAM, KANNAN | JOHNS HOPKINS UNIVERSITY, MD | $783,954 | NSD |
| 2018 | Antisense Oligonucleotides for treating Spinocerebellar Ataxia Type 21U01NS103883-01 | PULST, STEFAN M.SCOLES, DANIEL R | UNIVERSITY OF UTAH, UT | $589,341 | NSD |
| 2018 | Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 31U01NS106670-01 | MCLOUGHLIN, HAYLEY SARAHPAULSON, HENRY L | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $536,480 | NSD |
| 2017 | Development of Therapeutic Antibody for Traumatic Brain Injury1U01NS096835-01A1 | LU, KUN PING | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,374,083 | NSD |
| 2017 | A strategy for pharmacological treatment of global cerebral ischemia1U01NS094261-01A1 | BAYER, K. ULRICH | UNIVERSITY OF COLORADO DENVER, CO | $776,926 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.